Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05277116 · ClinicalTrials.gov registry record · NA
The Electronic Medical Records and GEnomics (eMERGE) Network Genomic Risk Assessment
A NA study of Genetic Disease, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- NA
- Development phase
- 26,877
- Enrollment target
- 12
- Study locations
NCT05277116: Active NA study of Genetic Disease, sponsored by Vanderbilt University Medical Center.
NCT05277116 is a NA study of Genetic Disease that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 26,877 participants, above the 1,665-participant average among 30 other Genetic Disease trials with a reported enrollment target (1514% higher). The trial reports 12 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05277116, a NA study of Genetic Disease, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 26,877 participants
- Enrollment target
- 12
- Study locations
Study Summary
The eMERGE Network embraces the opportunity to use new methods in genomic medicine, information science, and research participant engagement to identify people at very high risk for specific diseases and recommend individualized approaches to prevention and care. The investigators will conduct a prospective study, with diverse and underserved participants, across ten eMERGE study sites to evaluate clinical implementation of a Genome Informed Risk Assessment (GIRA) tool that combines genetic, family history, and clinical risk information from participants.
Primary Outcome
Number of new health care actions will be measured by electronic health record data and participant-reported outcomes through a REDCap survey. Pre-specified actions will include a condition-specific composite of new encounters, clinical orders, or specialty referrals for clinical evaluation associated with the condition(s), placed by a provider within 6 months of result disclosure.
Conditions Studied
Interventions
- OTHER Genome Informed Risk Assessment (GIRA) report
Study Locations (12)
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
New York
- Mount Sinai - New York
- Columbia University - New York
Alabama
- University of Alabama Birmingham - Birmingham
Arizona
- Mountain Park Health Center - Tempe
Illinois
- Northwestern - Chicago
Minnesota
- Mayo Clinic - Rochester
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26,877 participants |
| Start Date | 2022-02-16 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What the registry record for NCT05277116 still lists
NCT05277116 is an interventional study that assigns participants to a tested intervention. Its 26,877 participants enrollment target places it among the larger protocols in the corpus, above the 1,665-participant average among 30 other Genetic Disease trials with a reported enrollment target (1514% higher).
The record links to 1 condition, with Genetic Disease appearing as the primary indexed condition, and to 1 intervention - of which Genome Informed Risk Assessment (GIRA) report is the first listed.
NCT05277116 lists 12 locations in 10 states (Massachusetts, New York, Alabama).
Frequently Asked Questions
What is clinical trial NCT05277116 about?
NCT05277116 is a clinical study titled "The Electronic Medical Records and GEnomics (eMERGE) Network Genomic Risk Assessment". The eMERGE Network embraces the opportunity to use new methods in genomic medicine, information science, and research participant engagement to identify people at very high risk for specific diseases and recommend individualized approaches to prevention and care. The investigators will conduct a pro...
What is the current status of trial NCT05277116?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 26,877 participants. The study started on 2022-02-16. Estimated completion is 2026-12-31.
What conditions does trial NCT05277116 study?
This clinical trial studies the following conditions: Genetic Disease.
What interventions are being tested in trial NCT05277116?
The interventions under investigation include: Genome Informed Risk Assessment (GIRA) report (OTHER).
Who is sponsoring clinical trial NCT05277116?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05277116 being conducted?
This trial has 12 study locations across Alabama, Arizona, Illinois, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05277116's enrollment target sits among peer trials
26,877 1st of 30 higher than 30 of 30 other Genetic Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Genetic Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Adaptive Clinical Trial of BeginNGS Newborn Screening for Hundreds of Genetic Diseases by Genome Sequencing
RECRUITING · NA
-
Large Language Models To Improve the Quality of Care of Cardiology Patients
RECRUITING · NA
-
Grand Valley State University (GVSU) Skills on Wheels
ACTIVE NOT RECRUITING · NA
-
Clinical Decision Support to Identify Pediatric Patients With Undiagnosed Genetic Disease
ACTIVE NOT RECRUITING · NA
-
Overcoming Barriers to Accessing Genetic Medicine
ACTIVE NOT RECRUITING · NA
-
Pediatric Powered Wheelchair Standing Devices: An Exploratory Study
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04678193 · 27,000 participants
COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy
- NCT04494945 · 27,500 participants · NA
Identifying and Caring for Individuals With Inherited Cancer Syndrome
- NCT07300839 · 25,500 participants · Phase 3
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
- NCT03175302 · 25,240 participants
PREsurgical Cognitive Evaluation Via Digital clockfacEdrawing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI